NRG Oncology
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.nrgoncology.org
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 16
- Registration Number
- NCT04158141
- Locations
- 🇨🇦
The Research Institute of the McGill University Health Centre (MUHC), Montreal, Quebec, Canada
🇺🇸Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
- Conditions
- Stage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIA Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IIB Prostate Cancer AJCC v8Prostate AdenocarcinomaStage IIIB Prostate Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 586
- Registration Number
- NCT04134260
- Locations
- 🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
🇺🇸Mercy Cancer Center - Carmichael, Carmichael, California, United States
🇺🇸Mercy San Juan Medical Center, Carmichael, California, United States
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- NRG Oncology
- Registration Number
- NCT04105374
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Ovarian Low Grade Serous AdenocarcinomaPrimary Peritoneal Low Grade Serous AdenocarcinomaStage IV Primary Peritoneal Cancer AJCC v8Low Grade Fallopian Tube Serous AdenocarcinomaStage II Fallopian Tube Cancer AJCC v8Stage II Ovarian Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage IV Fallopian Tube Cancer AJCC v8Stage II Primary Peritoneal Cancer AJCC v8Stage III Fallopian Tube Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 450
- Registration Number
- NCT04095364
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Keck Medicine of USC Koreatown, Los Angeles, California, United States
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 1408
- Registration Number
- NCT04068103
- Locations
- 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Kaiser Permanente South Bay, Harbor City, California, United States
🇺🇸Springfield Memorial Hospital, Springfield, Illinois, United States
Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 22
- Registration Number
- NCT04037254
- Locations
- 🇺🇸
Benefis Sletten Cancer Institute, Great Falls, Montana, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
- Conditions
- Interventions
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 350
- Registration Number
- NCT03997370
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸The Hospital of Central Connecticut, New Britain, Connecticut, United States
Survivorship Care Planning for Prostate Cancer Survivors
- Conditions
- Interventions
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 834
- Registration Number
- NCT03860961
- Locations
- 🇺🇸
Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan, United States
🇺🇸Kingman Regional Medical Center, Kingman, Arizona, United States
🇺🇸Kaiser Permanente Dublin, Dublin, California, United States
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
- Conditions
- Clinical Stage I Esophageal Adenocarcinoma AJCC v8Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 300
- Registration Number
- NCT03801876
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸University Hospitals Sharon Health Center, Wadsworth, Ohio, United States
🇺🇸Corewell Health Dearborn Hospital, Dearborn, Michigan, United States
BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER
- Conditions
- Interventions
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 311
- Registration Number
- NCT03371719
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Scottsdale, Scottsdale, Arizona, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States